Insider Buying: Vanda Pharmaceuticals (NASDAQ:VNDA) Director Buys $13,167.54 in Stock

November 6, 2026 by InsiderTrades.com

Key Points

Director Charles Duncan bought 10,000 shares of Vanda Pharmaceuticals from November 3–5 for about $38,069, increasing his stake.
Shares were reported down 7.5%, opening Friday at $3.59, near the company’s 12-month low of $3.57.
Vanda beat quarterly estimates, reporting a loss of $0.37 per share versus analysts’ expected loss of $0.68, and revenue of $69.81 million versus a $69.20 million estimate.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) Director Charles Duncan purchased 3,447 shares of the firm's stock in a transaction that occurred on Wednesday, November 4th. The shares were acquired at an average cost of $3.82 per share, with a total value of $13,167.54. Following the completion of the purchase, the director directly owned 102,898 shares in the company, valued at $393,070.36. The trade was a 3.47% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Charles Cliff Duncan also recently made the following trade(s):

On Thursday, November 5th, Charles Duncan bought 5,803 shares of Vanda Pharmaceuticals stock. The shares were bought at an average cost of $3.80 per share, with a total value of $22,051.40.
On Tuesday, November 3rd, Charles Duncan bought 750 shares of Vanda Pharmaceuticals stock. The shares were bought at an average cost of $3.80 per share, with a total value of $2,850.00.

Vanda Pharmaceuticals Trading Down 7.5%

NASDAQ VNDA opened at $3.59 on Friday. The company's 50-day moving average price is $4.66 and its 200-day moving average price is $6.14. The company has a current ratio of 1.54, a quick ratio of 1.53 and a debt-to-equity ratio of 0.01. The stock has a market cap of $217.09 million, a PE ratio of -0.78 and a beta of 0.74. Vanda Pharmaceuticals Inc. has a 12 month low of $3.57 and a 12 month high of $9.94.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.68) by $0.31. The company had revenue of $69.81 million during the quarter, compared to analyst estimates of $69.20 million. Vanda Pharmaceuticals had a negative net margin of 119.87% and a negative return on equity of 62.70%. Equities research analysts forecast that Vanda Pharmaceuticals Inc. will post -2.53 earnings per share for the current year.

Vanda Pharmaceuticals News Summary

Here are the key news stories impacting Vanda Pharmaceuticals this week:

Positive Sentiment: Director Charles Cliff Duncan bought a combined 10,000 shares from November 3–5 for approximately $38,069, increasing his ownership. SEC ownership filing
Neutral Sentiment: HC Wainwright maintained its Buy rating and raised its 2026 EPS estimate to a loss of $2.45 from a loss of $3.03, including a narrower projected Q4 loss.
Negative Sentiment: HC Wainwright lowered estimates for Q2–Q4 2027 and cut its full-year 2027 EPS forecast to a loss of $1.02 from a loss of $0.94, signaling a less favorable outlook for those periods.

Institutional Trading of Vanda Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Cornerstone Wealth Management LLC purchased a new position in Vanda Pharmaceuticals during the 3rd quarter valued at about $83,000. AIGH Capital Management LLC raised its holdings in shares of Vanda Pharmaceuticals by 10.1% in the 3rd quarter. AIGH Capital Management LLC now owns 2,250,000 shares of the biopharmaceutical company's stock valued at $11,048,000 after purchasing an additional 205,831 shares in the last quarter. State Street Corp raised its holdings in shares of Vanda Pharmaceuticals by 16.6% in the 2nd quarter. State Street Corp now owns 3,516,405 shares of the biopharmaceutical company's stock valued at $21,520,000 after purchasing an additional 500,843 shares in the last quarter. Syon Capital LLC purchased a new stake in shares of Vanda Pharmaceuticals in the 2nd quarter worth approximately $125,000. Finally, Hsbc Holdings PLC lifted its position in shares of Vanda Pharmaceuticals by 144.5% in the 2nd quarter. Hsbc Holdings PLC now owns 94,988 shares of the biopharmaceutical company's stock worth $579,000 after purchasing an additional 56,133 shares during the period. 88.14% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

VNDA has been the subject of several research analyst reports. B. Riley Financial reaffirmed a "buy" rating and set a $12.00 price target (down from $17.00) on shares of Vanda Pharmaceuticals in a research note on Monday, August 10th. Oppenheimer assumed coverage on Vanda Pharmaceuticals in a research note on Wednesday, September 23rd. They issued an "outperform" rating and a $10.00 price objective on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Vanda Pharmaceuticals in a report on Thursday, October 15th. HC Wainwright reaffirmed a "buy" rating on shares of Vanda Pharmaceuticals in a research report on Monday. Finally, Wall Street Zen upgraded Vanda Pharmaceuticals from a "strong sell" rating to a "sell" rating in a report on Saturday, October 31st. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $13.50.

Read Our Latest Stock Analysis on Vanda Pharmaceuticals

Vanda Pharmaceuticals Company Profile

(Get Free Report)

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.

Vanda's marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.